Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin in metastatic castration-resistant prostate cancer
ACTRN12617000965303Phase 2Recruiting
- Sponsor
- Chris O'Brien Lifehouse
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of simvastatin in prostate cancer (PCa), sponsored by Chris O'Brien Lifehouse. Primary endpoint: Presence of a poor prognostic plasma lipid signature. Started May 2018; status: recruiting.
02
Drugs
simvastatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12617000965303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000965303.